Truist Raises Price Target on Amneal Pharmaceuticals to $15, Citing Strength in Affordable Medicines

Truist Financial raised its price target on Amneal Pharmaceuticals (NASDAQ: AMRX) to $15 from $14 while maintaining a Buy rating, pointing to continued strength in the affordable medicines market heading into 2026.

In a note dated January 7, Truist analysts said they believe the “affordable medicines” theme remains attractive and positions Amneal well for sustained growth. The firm highlighted Amneal’s expanding biosimilars portfolio and improving profitability profile as key drivers supporting the higher valuation. The price target increase follows recent regulatory progress by Amneal. In December, the company and its partner mAbxience received U.S. Food and Drug Administration approval for two denosumab biosimilars… Boncresa™, referencing Prolia®, and Oziltus™, referencing XGEVA®. Denosumab is a monoclonal antibody widely used in oncology and osteoporosis-related conditions to inhibit bone resorption.

Under the partnership, Amneal holds exclusive commercialization rights in the U.S., while mAbxience is responsible for manufacturing and development. The approvals expand Amneal’s commercial biosimilars portfolio to five products, reinforcing management’s view that biosimilars represent a significant long-term growth opportunity within its Affordable Medicines segment.Co-Chief Executive Officers Chirag and Chintu Patel have previously said the company sees biosimilars as a key pillar of future growth, particularly as healthcare systems increasingly seek lower-cost alternatives to branded biologics.

Truist also pointed to Amneal’s broader pipeline momentum, including ongoing product launches and contributions from its specialty portfolio, such as its Parkinson’s disease franchise. Analysts expect the company to achieve profitability this year, further supporting a constructive outlook.

Amneal shares have been among the stronger performers in the pharmaceutical sector, gaining roughly 62% over the past year and recently trading near a 52-week high. Truist said the company’s positioning across generics, specialty medicines, and biosimilars makes it well suited to benefit from sustained demand for cost-effective therapies.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals (NASDAQ: AMRX) is a global pharmaceutical company focused on developing, manufacturing, and distributing a broad portfolio of generic, specialty, and biosimilar medicines. The company operates across Generics, Specialty, and AvKARE segments, with a strategic emphasis on expanding access to affordable, high-quality treatments across multiple therapeutic areas.

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.